Clinical trials
Completed Coronary Stenosis trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Abbott Medical Devices | 4 |
| China National Center for Cardiovascular Diseases | 1 |
| DK Medical Technology (Suzhou) Co., Ltd. | 1 |
| Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 1 |
| JW Medical Systems Ltd | 1 |
| Shenzhen Raysight Intelligent Medical Technology Co., Ltd. | 1 |
| Sino Medical Sciences Technology Inc. | 1 |
| TEDA International Cardiovascular Hospital | 1 |
| The First Affiliated Hospital of Dalian Medical University | 1 |
| Yinyi(Liaoning) Biotech Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Coronary Stenosis | 14 |
| Coronary Artery Disease | 8 |
| Coronary Disease | 4 |
| Coronary Restenosis | 4 |
| Myocardial Ischemia | 4 |
| Vascular Diseases | 4 |
| Cardiovascular Diseases | 2 |
| Angina Pectoris | 1 |
| Arteriosclerosis | 1 |
| Coronary Occlusion | 1 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.